Key result
Clopidogrel was associated with a shorter mean time to first vascular thromboembolic event (1.2 weeks vs 1.8 weeks, HR 0.27) compared to beraprost sodium in patients with end-stage renal disease.
Why the study?
The study aimed to assess the time to first on-study vascular thromboembolic events with clopidogrel versus beraprost sodium in Chinese patients with end-stage renal disease undergoing arteriovenous fistula surgery.
Does clopidogrel compared to beraprost sodium increase the risk of vascular thromboembolic events in Chinese patients with end-stage renal disease undergoing arteriovenous fistula surgery?
Cohort (n=222)
Yes
Does clopidogrel compared to beraprost sodium increase the risk of vascular thromboembolic events in Chinese patients with end-stage renal disease undergoing arteriovenous fistula surgery?
In Chinese patients with ESRD undergoing AVF surgery, clopidogrel was associated with a significantly higher risk of early vascular thromboembolic events compared to beraprost sodium.
Clopidogrel was associated with higher early thromboembolic risk after AVF in ESRD; leaves open optimal choice pending randomized trials.
BACKGROUND: To assess the time to first on-study vascular thromboembolic events (VTEs) of clopidogrel (CL) or beraprost sodium (BPS) in Chinese population with end-stage renal disease (ESRD) treated with arteriovenous fistula (AVF) surgery. METHODS: From Jan 2009 to May 2015, 346 ESRD cases suffering an AVF surgery and undergoing oral administration of 75 mg CL (initial dose of 300 mg), 1 time/day, for 4 weeks or 40 μg BPS, 3 times/day, for 4 weeks were retrospectively assessed. The primary outcome was time to first on-study VTE. RESULTS: In total, 222 ESRD cases (CL, n = 112; BPS, n = 110) were assessed, with a median follow-up time of 38.1 months (range, 37-40 months). The mean time to first on-study VTE was 1.2 weeks (0.5-2.3) and 1.8 weeks (1.2-3.8) for CL and BPS, respectively (HR 0.27, 95% CI 0.16-1.45; P = 0.00). An increased incidence of VTEs was found during the 1th-month follow-up, with rates of 14.2 and 5.5% for CL and BPS, respectively (P = 0.03). The difference persisted over time, with rates of 24.1 and 11.8% at final follow-up, respectively (P = 0.02). CONCLUSION: CL with an increased risk of VTEs tended to have a VTE within the 1st month after cessation compared with BPS.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2018) conducted a cohort in end-stage renal disease (ESRD) treated with arteriovenous fistula (AVF) surgery (n=222). Clopidogrel vs. Beraprost sodium was evaluated on time to first on-study vascular thromboembolic event (VTE) (HR 0.27, 95% CI 0.16-1.45, p=0.00). Clopidogrel was associated with a shorter mean time to first vascular thromboembolic event (1.2 weeks vs 1.8 weeks, HR 0.27) compared to beraprost sodium in patients with end-stage renal disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: